Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move
across top level links and expand / close menus in sub levels. Up and Down arrows will open main level
menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab
will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Any of the four RAC exams (US, EU, CAN or Global) may be taken at any location. Find an upcoming exam at a location near you.
Posted 29 February 2012 | By Alexander Gaffney, RAC
An Institute of Medicine (IOM) report released 29 February praises the effects of the Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children Act (BPCA) on safe and effective medicinal practices in children, but calls for further expansion of pediatric studies.
The report, entitled Safe and Effective Medicines for Children: Pediatric Studies Conducted Under BPCA and PREA, was commissioned at the request of the US Food and Drug Administration (FDA), which wanted the review done before PREA and BPCA come up for renewal by the Congress this year.
The report notes that more than 400 drugs have been studied under the acts-a radical departure from when many drug companies simply recommended prescribing drugs to children off-label rather than conduct costly and difficult pediatric clinical trials.
The report recommends FDA require sponsors to conduct long-term follow-up clinical trials in children more frequently and address the lack of testing in newborns and premature infants by providing more resources.
IOM: Federal Laws Have Enhanced Pediatric Drug Studies; IOM Report Identifies Options for Further Improvements
IOM: Safe and Effective Medicines for Children: Pediatric Studies Conducted Under BPCA and PREA
Tags: Children, IOM, Pediatric, PREA, BPCA, Report, Latest News, study, clinical trials
Regulatory Focus newsletters
All the biggest regulatory news and happenings.